Honey and Nigella Sativa in COVID-19 Prophylaxis (HNS-COVID-PK)

Sohaib Ashraf

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Covid19

Treatments: Drug: Honey; Drug: Nigella sativa seed; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04767087

SZMC/IRB/Internal/273/2021

Details and patient eligibility

About

Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Health care professionals Post-exposure COVID-19

Exclusion criteria

• Multi-organ failure active COVID-19

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

1,000 participants in 2 patient groups, including a placebo group

Honey and Nigella sativa Arm

Active Comparator group

Description:

0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds

Treatment:

Drug: Nigella sativa seed

Drug: Honey

Placebo Arm

Placebo Comparator group

Description:

empty capsule with sugar water

Treatment:

Other: Placebo